Merck
CN
  • Injectable cultured bone marrow-derived mesenchymal stem cells in varus knees with cartilage defects undergoing high tibial osteotomy: a prospective, randomized controlled clinical trial with 2 years' follow-up.

Injectable cultured bone marrow-derived mesenchymal stem cells in varus knees with cartilage defects undergoing high tibial osteotomy: a prospective, randomized controlled clinical trial with 2 years' follow-up.

Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association (2013-11-30)
Keng Lin Wong, Kevin Boon Leng Lee, Bee Choo Tai, Ping Law, Eng Hin Lee, James H P Hui
摘要

To analyze the results of the use of intra-articular cultured autologous bone marrow-derived mesenchymal stem cell (MSC) injections in conjunction with microfracture and medial opening-wedge high tibial osteotomy (HTO). Fifty-six knees in 56 patients with unicompartmental osteoarthritic knees and genu varum were randomly allocated to the cell-recipient group (n = 28) or control group (n = 28). Patients who had a joint line congruity angle of more than 2°, malalignment of the knee from femoral causes, a fixed flexion deformity, or age older than 55 years were excluded. All patients underwent HTO and microfracture. The cell-recipient group received intra-articular injection of cultured MSCs with hyaluronic acid 3 weeks after surgery, whereas the control group only received hyaluronic acid. The primary outcome measure was the International Knee Documentation Committee (IKDC) score at intervals of 6 months, 1 year, and 2 years postoperatively. Secondary outcome measures were Tegner and Lysholm clinical scores and 1-year postoperative Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) scores. The median age of the patients was 51 years, with a mean body mass index of 23.85. Both treatment arms achieved improvements in Tegner, Lysholm, and IKDC scores. After adjustment for age, baseline scores, and time of evaluation, the cell-recipient group showed significantly better scores. The effect of treatment showed an added improvement of 7.65 (95% confidence interval [CI], 3.04 to 12.26; P = .001) for IKDC scores, 7.61 (95% CI, 1.44 to 13.79; P = .016) for Lysholm scores, and 0.64 (95% CI, 0.10 to 1.19; P = .021) for Tegner scores. Magnetic resonance imaging scans performed 1 year after surgical intervention showed significantly better MOCART scores for the cell-recipient group. The age-adjusted mean difference in MOCART score was 19.6 (95% CI, 10.5 to 28.6; P < .001). Intra-articular injection of cultured MSCs is effective in improving both short-term clinical and MOCART outcomes in patients undergoing HTO and microfracture for varus knees with cartilage defects. Level II, randomized controlled trial.

材料
货号
品牌
产品描述

Sigma-Aldrich
透明质酸 钠盐 来源于马链球菌, bacterial glycosaminoglycan polysaccharide
Sigma-Aldrich
透明质酸 钠盐 来源于公鸡鸡冠, avian glycosaminoglycan polysaccharide
透明质酸钠, BRP, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
透明质酸 钠盐 来源于牛玻璃体液
Sigma-Aldrich
透明质酸 钠盐 来源于马链球菌, mol wt 1,000,000-1,250,000
Sigma-Aldrich
透明质酸 钠盐 来源于马链球菌, mol wt 8,000-15,000
Sigma-Aldrich
透明质酸 钠盐 来源于兽疫链球菌, bacterial glycosaminoglycan polysaccharide
Sigma-Aldrich
透明质酸 钠盐 来源于马链球菌, mol wt 300,000-500,000
Sigma-Aldrich
透明质酸 钠盐 来源于马链球菌, mol wt 30,000-50,000
Sigma-Aldrich
透明质酸 钠盐 来源于马链球菌, mol wt 1,200
Sigma-Aldrich
透明质酸 钠盐 来源于马链球菌, mol wt 50,000-70,000
Sigma-Aldrich
透明质酸 钠盐 来源于马链球菌, mol wt 1,500,000-1,750,000
Sigma-Aldrich
透明质酸 钠盐 来源于马链球菌, mol wt 2,000,000-2,400,000
Sigma-Aldrich
透明质酸 钠盐 来源于马链球菌, mol wt 10,000-30,000
Sigma-Aldrich
透明质酸 钠盐 来源于马链球菌, mol wt 70,000-120,000
Sigma-Aldrich
透明质酸 钠盐 来源于马链球菌, mol wt 15,000-30,000
Sigma-Aldrich
透明质酸 钠盐 来源于马链球菌, mol wt 2,000,000-2,200,000
Sigma-Aldrich
透明质酸 钠盐 来源于马链球菌, mol wt 120,000-350,000